ADVANCED
PATHOPHARMACOLOGICAL
FOUNDATIONS (D027)
COMPREHENSIVE QUESTIONS AND
ANSWERS
1. Which process involves the addition of a methyl group to a cytosine base followed by a
guanine base, leading to gene silencing without altering the DNA sequence?
A. Histone Acetylation
B. RNA Splicing
C. DNA Methylation
D. Gene Amplification
Answer: C
Conceptual Explanation: DNA methylation is an epigenetic mechanism where a methyl
group is added to the C5 position of the cytosine ring, typically in CpG islands, resulting in
the inhibition of gene transcription.
,2. A patient with chronic hypertension exhibits thickening of the left ventricular wall. This
cellular adaptation is best described as:
A. Metaplasia
B. Hyperplasia
C. Hypertrophy
D. Atrophy
Answer: C
Conceptual Explanation: Hypertrophy is an increase in the size of cells (and consequently
the organ) in response to increased workload, such as the heart pumping against high
systemic pressure.
3. Which pathophysiological mechanism is primary in the development of Type 1 Diabetes
Mellitus?
A. Insulin resistance in peripheral tissues
B. Decreased incretin secretion
C. Excessive glucagon production by alpha cells
D. T-cell mediated autoimmune destruction of pancreatic beta cells
Answer: D
, Conceptual Explanation: Type 1 Diabetes is characterized by the autoimmune destruction
of insulin-producing beta cells in the Islets of Langerhans, predominantly mediated by T-
lymphocytes.
4. A patient is prescribed Memantine for Alzheimer’s disease. What is the pharmacological
mechanism of this drug?
A. Cholinesterase inhibition
B. NMDA receptor antagonism
C. Dopamine agonism
D. Serotonin reuptake inhibition
Answer: B
Conceptual Explanation: Memantine works as a low-to-moderate affinity noncompetitive
NMDA receptor antagonist, preventing over-excitation of glutamate receptors which is
neurotoxic.
5. In the Renin-Angiotensin-Aldosterone System (RAAS), which enzyme is responsible for
converting Angiotensin I to Angiotensin II?
A. Renin
B. Angiotensin-Converting Enzyme (ACE)
C. Aldosterone Synthase
D. Neprilysin
PATHOPHARMACOLOGICAL
FOUNDATIONS (D027)
COMPREHENSIVE QUESTIONS AND
ANSWERS
1. Which process involves the addition of a methyl group to a cytosine base followed by a
guanine base, leading to gene silencing without altering the DNA sequence?
A. Histone Acetylation
B. RNA Splicing
C. DNA Methylation
D. Gene Amplification
Answer: C
Conceptual Explanation: DNA methylation is an epigenetic mechanism where a methyl
group is added to the C5 position of the cytosine ring, typically in CpG islands, resulting in
the inhibition of gene transcription.
,2. A patient with chronic hypertension exhibits thickening of the left ventricular wall. This
cellular adaptation is best described as:
A. Metaplasia
B. Hyperplasia
C. Hypertrophy
D. Atrophy
Answer: C
Conceptual Explanation: Hypertrophy is an increase in the size of cells (and consequently
the organ) in response to increased workload, such as the heart pumping against high
systemic pressure.
3. Which pathophysiological mechanism is primary in the development of Type 1 Diabetes
Mellitus?
A. Insulin resistance in peripheral tissues
B. Decreased incretin secretion
C. Excessive glucagon production by alpha cells
D. T-cell mediated autoimmune destruction of pancreatic beta cells
Answer: D
, Conceptual Explanation: Type 1 Diabetes is characterized by the autoimmune destruction
of insulin-producing beta cells in the Islets of Langerhans, predominantly mediated by T-
lymphocytes.
4. A patient is prescribed Memantine for Alzheimer’s disease. What is the pharmacological
mechanism of this drug?
A. Cholinesterase inhibition
B. NMDA receptor antagonism
C. Dopamine agonism
D. Serotonin reuptake inhibition
Answer: B
Conceptual Explanation: Memantine works as a low-to-moderate affinity noncompetitive
NMDA receptor antagonist, preventing over-excitation of glutamate receptors which is
neurotoxic.
5. In the Renin-Angiotensin-Aldosterone System (RAAS), which enzyme is responsible for
converting Angiotensin I to Angiotensin II?
A. Renin
B. Angiotensin-Converting Enzyme (ACE)
C. Aldosterone Synthase
D. Neprilysin
